Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05234736 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers
A Phase 2 study, sponsored by Caliway Biopharmaceuticals Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT05234736: Completed Phase 2 study, sponsored by Caliway Biopharmaceuticals Co..
NCT05234736 is a Phase 2 study that has completed, run by Caliway Biopharmaceuticals Co.. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05234736, a Phase 2 study, has completed, sponsored by Caliway Biopharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This Phase 2 study will be an open-label and single course study to assess the safety, tolerability, PK and metabolite profile of CBL-514.
Primary Outcome
To evaluate maximum analyte concentration of CBL-514 in plasma (Cmax) after single dose injection.
Interventions
- DRUG CBL-514
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-02-11 |
| Est. Completion | 2022-06-09 |
| Phase | Phase 2 |
What the finished NCT05234736 record still lists
NCT05234736 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which CBL-514 is the first listed.
NCT05234736 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05234736 about?
NCT05234736 is a clinical study titled "A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers". This Phase 2 study will be an open-label and single course study to assess the safety, tolerability, PK and metabolite profile of CBL-514.
What is the current status of trial NCT05234736?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2022-02-11. Estimated completion is 2022-06-09.
What interventions are being tested in trial NCT05234736?
The interventions under investigation include: CBL-514 (DRUG).
Who is sponsoring clinical trial NCT05234736?
This trial is sponsored by Caliway Biopharmaceuticals Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05234736's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI